← Back to all trials
Withdrawn
NCT02893618
A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)
Conditions: Prader-Willi Syndrome
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE2
Sponsor: Essentialis, Inc.
Summary
Open label, parallel-group, single site, 5 treatment-period study with 4 dose levels of DCCR, 1 of which is administered both with and without food.
Eligibility Criteria
Inclusion Criteria:
* Ability to follow verbal and written instructions
* Informed consent form signed by the subject
* Completed screening within 7 days prior to dosing
* BMI between 18.5 and 35 kg/m2
* Generally healthy
* fasting glucose less than or equal to 100 mg/dL
* HbA1c less than or equal to 6%
Exclusion Criteria:
* Pregnancy or breast feeding
* absence of contraception
* administration of investigational drug within 1 month prior to screening
* anticipated requirement for prohibited medication (systemic corticosteroids or anti-diabetic medications)
* allergic reaction to or significant intolerance of diazoxide, thiazides or sulfonamides
* known type 1 or type 2 diabetes mellitus
* congestive heart failure
* gastric bypass surgery
* history of drug or alcohol abuse
Source: ClinicalTrials.gov (NCT02893618). StuddyBuddy aggregates publicly available trial information.